CN5 - COST-EFFECTIVENESS OF PEMBROLIZUMAB VERSUS...

Value in Health 2018 / 10 Vol. 21

CN5 - COST-EFFECTIVENESS OF PEMBROLIZUMAB VERSUS STANDARD-OF-CARE CHEMOTHERAPIES FOR FIRST-LINE TREATMENT OF PD-L1 POSITIVE (≥50%) METASTATIC NON-SMALL CELL LUNG CANCER IN FRANCE

Chouaid, C., Bensimon, L., Clay, E., Millier, A., Lévy-Bachelot, L., Huang, M., Levy, P.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
21
Journal:
Value in Health
DOI:
10.1016/j.jval.2018.09.022
Date:
October, 2018
File:
PDF, 313 KB
2018
Conversion to is in progress
Conversion to is failed